1. Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01
- Author
-
Jong Hoon Lee, Ju Ree Kim, Yeon Sil Kim, Seok Ho Lee, Mee Sun Yoon, Jinhee Kim, Sea-Won Lee, Songmi Jeong, Bae Kwon Jeong, Keun Yong Eom, and Ja Young Lee
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Brachytherapy ,Uterine Cervical Neoplasms ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Antigens, Neoplasm ,Predictive Value of Tests ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Progression-free survival ,Stage (cooking) ,Serpins ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Cervical cancer ,Gynecology ,Framingham Risk Score ,business.industry ,Obstetrics and Gynecology ,Odds ratio ,Middle Aged ,Prognosis ,medicine.disease ,Magnetic Resonance Imaging ,Confidence interval ,Survival Rate ,Radiation therapy ,030220 oncology & carcinogenesis ,Female ,business - Abstract
Objective The aim of this multi-institutional study was to determine the prognostic impact of tumour parameters, such as tumour size (TS), tumour volume (TV), and marker expression, on survival during radiation therapy (RT) for cervical cancer patients. Methods A total of 231 patients with histologically confirmed cervical cancer, classified as Federation of Gynecology and Obstetrics (FIGO) Ib2-IVa, were enrolled in this study. Pre- and mid-RT pelvic magnetic resonance imaging (MRI) and squamous cell carcinoma antigen (SCC-ag) analysis were performed twice, during RT and just before brachytherapy. Results The median follow-up time was 27.8months (range, 2–116months). Multivariate analysis revealed that stage (odds ratio [OR], 2.936 and 95% confidence interval [CI], 1.119–7.707; P =0.029), tumour volume reduction rate (TVRR) (OR, 3.435 and 95% CI, 1.062–11.106; P =0.039), and SCC-ag reduction rate (SCCRR) (OR, 5.104 and 95% CI, 1.769–14.727; P =0.003) were independently associated with overall survival (OS), while pre-RT TS (OR, 2.148 and 95% CI, 1.221–3.810; P =0.009), mid-RT TV (OR, 3.106 and 95% CI, 1.685–5.724; P P =0.016) were associated with progression-free survival (PFS). Based on the prognostic factor analysis, patients with the highest prognostic risk score of 3 showed poorer overall survival and progression free survival than patients with lower prognostic risk scores. Conclusion We identified that tumour parameters such as TVRR, SCCRR, pre-RT TS, and mid-RT TV areindependent and strong prognostic parameters for patients with cervical cancer receiving RT. This scoring system-based prognostic factor analysis could be used to help develop optimized treatment plans for cervical cancer patients during RT.
- Published
- 2017
- Full Text
- View/download PDF